An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers

Clinical Infectious Diseases

Volumn 52, Issue 4, 2011, Pages 522-531

  Van Braeckel, Eva ^a   Bourguignon, Patricia ^b   Koutsoukos, Marguerite ^b   Clement, Frédéric ^a   Janssens, Michel ^b   Carletti, Isabelle ^b   Collard, Alix ^b   Demoitié, Marie Ange ^b   Voss, Gerald ^b   Leroux Roels, Geert ^a   McNally, Lisa ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; INTERLEUKIN 2; POLYPROTEIN; RECOMBINANT FUSION PROTEIN F4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL STIMULATION; CROSS REACTION; CYTOKINE PRODUCTION; DIARRHEA; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; SKIN REDNESS; STAINING; SWEATING; SWELLING; VACCINATION; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AIDS VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; HIV INFECTIONS; HIV-1; HUMAN EXPERIMENTATION; HUMANS; IMMUNIZATION, SECONDARY; MALE; RECOMBINANT FUSION PROTEINS; VACCINATION; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 79951823624     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq160     Document Type: Article

References (41)

1. Fauci AS. 25 years of HIV. Nature 2008;453:289-90. (Pubitemid 351693111)
2. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191:654-65.
3. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, doubleblind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006;194:1661-71. (Pubitemid 44901996)
4. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a doubleblind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881-93.
5. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-20.
6. Barouch DH, Letvin NL. CD8+ cytotoxic T lymphocyte responses to lentiviruses and herpesviruses. Curr Opin Immunol 2001;13:479-82. (Pubitemid 32728482)
7. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-5. (Pubitemid 24183063)
8. Jin X, Bauer DE, Tuttleton SE, et al. Dramatic rise in plasma viremia after CD8 (+) T cell depletion in simian immunodeficiency virusinfected macaques. J Exp Med 1999;189:991-8. (Pubitemid 29149355)
9. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006;107:4781-9. (Pubitemid 43882629)
10. Klenerman P, Hill A. T cells and viral persistence: lessons from diverse infections. Nat Immunol 2005;6:873-9. (Pubitemid 43090441)
11. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003;421:852-6. (Pubitemid 36254145)
12. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003;300:337-9. (Pubitemid 36433726)
13. Sun JC, Williams MA, Bevan MJ. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 2004;5:927-33. (Pubitemid 39276237)
14. Yang TC, Millar J, Groves T, et al. On the role of CD4+ T cells in the CD8+ T-cell response elicited by recombinant adenovirus vaccines. Mol Ther 2007;15:997-1006. (Pubitemid 46621659)
15. Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J Immunol 2002;169:6376-85. (Pubitemid 36903486)
16. Kannanganat S, Kapogiannis BG, Ibegbu C, et al. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J Virol 2007;81:12071-6. (Pubitemid 47623838)
17. Potter SJ, Lacabaratz C, Lambotte O, et al. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol 2007;81:3904-15.
18. Lichterfeld M, Kaufmann DE, Yu XG, et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med 2004;200:701-12. (Pubitemid 39299457)
19. Goepfert PA, Tomaras GD, Horton H, et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 2007;25:510-8. (Pubitemid 44856093)
20. +T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. Vaccine 2010;28:7016-24.
21. Lichterfeld M, Gandhi R, Flynn T, et al. Strong HIV-specific IL2+ CD4+ T cell responses induced by an HIV gp120/NefTat vaccine formulated with the AS02A adjuvant in HAART treated HIV+ individuals [abstract P09-02]. Presented at: AIDS Vaccine Conference, 2007; Seattle, WA.
22. Stewart VA, McGrath SM, Walsh DS, et al. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS, S/AS02A. Vaccine 2006;24:6483-92. (Pubitemid 44511857)
23. Mettens P, Dubois PM, Demoitié MA, et al. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS, S vaccine antigen. Vaccine 2008;26:1072-82.
24. Pichyangkul S, Kum-Arb U, Yongvanitchit K, et al. Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS, S/AS01B vaccine in rhesus primates. Infect Immun 2008;76:229-38.
25. Vandepapelière P, Horsmans Y, Moris P, et al. Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008;26:1375-86.
26. Garxcon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007;6:723-39. (Pubitemid 47607848)
27. Heeney JL. Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses. Expert Rev Vaccines 2004;3: S53-64. (Pubitemid 39120626)
28. Korber B T M, Brander C, Haynes BF et al, eds. HIV molecular immunology. Los Alamos, NM: Los Alamos National Laboratory, Theoretical Biology Biophysics, 2008.
29. Ferrari G, Kostyu DD, Cox J, et al. Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. AIDS Res Hum Retroviruses 2000;16:1433-43.
30. Yu XG, Lichterfeld M, Addo MM, Altfeld M. Regulatory and accessory HIV-1 proteins: potential targets for HIV-1 vaccines? Curr Med Chem 2005;12:741-7. (Pubitemid 40331063)
31. Maecker HT, Dunn HS, Suni MA, et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 2001;255:27-40.
32. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ. Jalview Version 2: a multiple sequence alignment editor and analysis workbench. Bioinformatics 2009;25:1189-91.
33. Kester KE, Cummings JF, Ofori-Anyinam O, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009;200:337-46.
34. Forgus S, Leroux-Roels I, De Boever F, et al. Safety and immunogenicity of the M72/AS01B and M72/AS02A candidate tuberculosis vaccines in PPD-negative Belgian adults. In: TBV 2008: TB Vaccines for the World,-11 April 2008. Atlanta, GA: Centers for Disease Control and Prevention, 2008.
35. Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 2007;81:8468-76. (Pubitemid 47242819)
36. Sun Y, Schmitz JE, Buzby AP, et al. Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge. J Virol 2006;80:10950-6. (Pubitemid 44706536)
37. Radosević K, Rodriguez A, Lemckert A, Goudsmit J. Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects. Expert Rev Vaccines 2009;8:577-92.
38. McMichael A, Mwau M, Hanke T. HIV T cell vaccines, the importance of clades. Vaccine 2002;20:1918-21. (Pubitemid 34450787)
39. Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002;417:95-8. (Pubitemid 34498823)
40. Rivas P, Herrero MD, Puente S, Ramírez-Olivencia G, Soriano V. Immunizations in HIV-infected adults. AIDS Rev 2007;9:173-87. (Pubitemid 350010542)
41. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008;372:1894-905.